Judith Klimovsky
Direktor/Vorstandsmitglied bei BIO-TECHNE CORPORATION
Vermögen: 2 Mio $ am 30.04.2024
Profil
Judith Klimovsky is an Independent Director at Bio-Techne Corp.
since 2024.
She is also the Chief Development Officer & Executive VP at Genmab A since 2017.
Previously, she worked as a Director at Bellicum Pharmaceuticals, Inc. from 2018 to 2024.
Prior to that, she held the position of Senior Vice President & Head-Clinical Development at Novartis AG from 2015 to 2017 and at Novartis Pharma AG from 2009 to 2017.
Dr. Klimovsky holds a doctorate degree from the University of Buenos Aires School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GENMAB A/S
0,01% | 14.02.2024 | 8 740 ( 0,01% ) | 2 Mio $ | 30.04.2024 |
BIO-TECHNE CORPORATION
0,00% | 01.05.2024 | 680 ( 0,00% ) | 42 609 $ | 30.04.2024 |
Aktive Positionen von Judith Klimovsky
| Unternehmen | Position | Beginn |
|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 09.02.2017 |
| BIO-TECHNE CORPORATION | Direktor/Vorstandsmitglied | 24.04.2024 |
Ehemalige bekannte Positionen von Judith Klimovsky
| Unternehmen | Position | Ende |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 23.02.2024 |
| NOVARTIS AG | Corporate Officer/Principal | 01.02.2017 |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.01.2017 |
Ausbildung von Judith Klimovsky
| University of Buenos Aires School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GENMAB A/S | Health Technology |
| NOVARTIS AG | Health Technology |
| BIO-TECHNE CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
